SCHEMBL26013286

SCHEMBL26013286

Cc1cc(C(C)C)ccc1-c1ccc([Si](C)(C)C)c[n+]1C

nearest known ligand 0.41

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
TRPA1 O75762 1/20 0.33
PTGS1 P23219 1/20 0.33
CACNA1C Q13936 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26013243 0.90 LMNA (0.46) LMNATRPA1PTGS1CACNA1C
SCHEMBL25450505 0.85 LMNA (0.48) LMNATRPA1PTGS1CACNA1C
SCHEMBL25885582 0.82 NPC1 (0.33) LMNA
SCHEMBL25450348 0.82 LMNA (0.46) LMNATRPA1PTGS1CACNA1C
SCHEMBL26014558 0.81 LMNA (0.42) LMNATRPA1PTGS1CACNA1C
SCHEMBL26014475 0.80 LMNA (0.41) LMNATRPA1PTGS1CACNA1C
SCHEMBL26013323 0.80 LMNA (0.41) LMNATRPA1PTGS1CACNA1C
SCHEMBL26013287 0.80 EDNRA (0.38)
SCHEMBL25475617 0.79 PDE3B (0.33)
SCHEMBL25475615 0.78 CYP1A2 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713333-B2 Organometallic compound, organic light-emitting device including the same, and diagnostic composition including the organometallic compound SAMSUNG ELECTRONICS CO., LTD. (KR) 2023-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11713333-B2 Organometallic compound, organic light-emitting device including the same, and diagnostic composition including the organometallic compound ORC3, LAGE3, ORMDL3 LMNA 3940/4885TRPA1 546/4885PTGS1 3908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.